菜单

Panjiva_research_logo

USMCA Watch: Eli Lilly Exports Slip, Pfizer Dosed Up As Drug Rules Are Abandoned

Canada 375 Health Care 140 Mexico 600 Trade Deals 797 U.S. 3918 USMCA 401

The administration of President Donald Trump may be willing to drop proposals related to standardized biologic drug patent lengths in order to secure passage of the U.S.-Mexico-Canada Agreement, USMCA, through the U.S. House of Representatives. Setting patent protections to 10 years across the region – currently the U.S. has 12 years of protections versus eight and five in Canada and Mexico – has been one of four demands from House Democrats. The move is unlikely to be popular with the pharmaceutical industry, but could help boost demand for Mexican drug imports from the U.S. Imports of ...

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2020 S&P Global. All Rights Reserved.